A 6-OH Trp amatoxin-linker boosts solid tumor cytotoxicity while cleavable antibody linkers balance targeted release and circulation stability.
An oral WS635 compound overcomes weak wound-care efficacy by inhibiting Cyclophilin D, promoting angiogenesis, and reducing wound area.
Position-4 OR4 substitution and a cleavable linker boost amatoxin antibody conjugate release and cytotoxicity against solid tumors.